LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy

Annals of Neurology

Volumn 73, Issue 4, 2013, Pages 481-488

  Flanigan, Kevin M ^a,b   Ceco, Ermelinda ^c   Lamar, Kay Marie ^c   Kaminoh, Yuuki ^a   Dunn, Diane M ^d   Mendell, Jerry R ^a,b   King, Wendy M ^b   Pestronk, Alan ^e   Florence, Julaine M ^e   Mathews, Katherine D ^f   Finkel, Richard S ^g   Swoboda, Kathryn J ^d   Gappmaier, Eduard ^h   Howard, Michael T ^d   Day, John W ⁱ   McDonald, Craig ^j   McNally, Elizabeth M ^c   Weiss, Robert B ^d  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF UTAH   (United States)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; DISEASE SEVERITY; DUCHENNE MUSCULAR DYSTROPHY; FIBROBLAST; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EXTRACELLULAR MATRIX PROTEINS; FEMALE; FIBROBLASTS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOTYPE; GLUCOCORTICOIDS; HUMANS; LATENT TGF-BETA BINDING PROTEINS; MALE; MOBILITY LIMITATION; MUSCULAR DYSTROPHY, DUCHENNE; POLYMORPHISM, SINGLE NUCLEOTIDE; SMAD PROTEINS;

EID: 84878390222     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23819     Document Type: Article

References (27)

1. Dent KM, Dunn DM, von Niederhausern AC, et al. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am J Med Genet A 2005; 134: 295-298.
2. Moxley RT III, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005; 64: 13-20.
3. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010; 9: 77-93.
4. Manzur AY, Kuntzer T, Pike M, Swan A,. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008;(1): CD003725.
5. King WM, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007; 68: 1607-1613.
6. McNally EM, Passos-Bueno MR, Bonnemann CG, et al. Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation. Am J Hum Genet 1996; 59: 1040-1047.
7. Kefi M, Amouri R, Driss A, et al. Phenotype and sarcoglycan expression in Tunisian LGMD 2C patients sharing the same del521-T mutation. Neuromuscul Disord 2003; 13: 779-787.
8. Heydemann A, Ceco E, Lim JE, et al. Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice. J Clin Invest 2009; 119: 3703-3712.
9. Todorovic V, Rifkin DB,. LTBPs, more than just an escort service. J Cell Biochem 2012; 113: 410-418.
10. Flanigan KM, Dunn DM, von Niederhausern A, et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat 2009; 30: 1657-1666.
11. Saharinen J, Keski-Oja J,. Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta. Mol Biol Cell 2000; 11: 2691-2704.
12. A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061-1073.
13. Flanigan KM, Dunn DM, von Niederhausern A, et al. Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene. Hum Mutat 2011; 32: 299-308.
14. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-249.
15. Ge G, Greenspan DS,. BMP1 controls TGFbeta1 activation via cleavage of latent TGFbeta-binding protein. J Cell Biol 2006; 175: 111-120.
16. Zhou Y, Koli K, Hagood JS, et al. Latent transforming growth factor-beta-binding protein-4 regulates transforming growth factor-beta1 bioavailability for activation by fibrogenic lung fibroblasts in response to bleomycin. Am J Pathol 2009; 174: 21-33.
17. Swaggart KA, Heydemann A, Palmer AA, McNally EM,. Distinct genetic regions modify specific muscle groups in muscular dystrophy. Physiol Genomics 2011; 43: 24-31.
18. Bernasconi P, Torchiana E, Confalonieri P, et al. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin Invest 1995; 96: 1137-1144.
19. Chen YW, Nagaraju K, Bakay M, et al. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 2005; 65: 826-834.
20. Cohn RD, van Erp C, Habashi JP, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007; 13: 204-210.
21. Goldstein JA, Kelly SM, LoPresti PP, et al. SMAD signaling drives heart and muscle dysfunction in a Drosophila model of muscular dystrophy. Hum Mol Genet 2011; 20: 894-904.
22. Nelson CA, Hunter RB, Quigley LA, et al. Inhibiting TGF-beta activity improves respiratory function in mdx mice. Am J Pathol 2011; 178: 2611-2621.
23. Pegoraro E, Hoffman EP, Piva L, et al. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 2011; 76: 219-226.
24. Hullinger TG, Pan Q, Viswanathan HL, Somerman MJ,. TGFbeta and BMP-2 activation of the OPN promoter: roles of smad- and hox-binding elements. Exp Cell Res 2001; 262: 69-74.
25. Hersh CP, Demeo DL, Lazarus R, et al. Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 977-984.
26. Forsti A, Li X, Wagner K, et al. Polymorphisms in the transforming growth factor beta 1 pathway in relation to colorectal cancer progression. Genes Chromosomes Cancer 2010; 49: 270-281.
27. Thompson AR, Cooper JA, Jones GT, et al. Assessment of the association between genetic polymorphisms in transforming growth factor beta, and its binding protein (LTBP), and the presence, and expansion, of abdominal aortic aneurysm. Atherosclerosis 2010; 209: 367-373.